Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva
- Registration Number
- NCT05453045
- Lead Sponsor
- Universidad Nacional de Salta
- Brief Summary
This project will develop and assess the feasibility and acceptability of a salive-based assay to monitor adherence to Mass Drug Administration (MDA) campaigns within Soil-transmitted helminthiasis (STH) control programs, evaluating the salive and serum pharmacokinetics of ALBENDAZOLE (ABZ) and its metabolites.The final goal is to obtain a field ready tool for the measurement of adherence to anthelmintic treatment at a community level that serves as a coverage/adherence indicator and a reference standard for other monitoring tools.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 12
Body Mass Index: 18 to 25.
Physical exam without significant abnormal findings.
Pregnancy
Lactation
Use of ABZ or other benzimidazole drugs in the previous 30 days
History of intolerance to ABZ
Malabsorption and/or other gastrointestinal conditions that might compromise ABZ absorption.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Albendazole Albendazole 400 mg po single dose
- Primary Outcome Measures
Name Time Method Salive albendazole levels 72 hours Albendazole and its metabolites will be measured in salive samples through high performance liquid chromatography (HPLC).
- Secondary Outcome Measures
Name Time Method